6533b835fe1ef96bd129f3d0

RESEARCH PRODUCT

Gestión de la devolución de tratamientos antineoplásicos y de su reutilización en pacientes oncológicos

subject

description

Objective: Analyse the profi le of parenteral preparation and treatment (anti-neoplastic and supplementary) that were dispensed and returned to the Pharmacy Department, the reasons why they were not administered, their reuse and the associated direct costs. Method: Longitudinal study over eight months (October 2004-May 2005) in a tertiary hospital with centre for preparing anti-neoplastic agents (including supplementary treatment) in its Pharmacy Department. The variables studied, downloaded from the Oncofarm® application, are as follows: a) patients and diagnostics; b) returned treatments, classifi ed by reason returned, pharmaco-therapeutic scheme, cycle and day; c) returned preparations (anti-neoplastic and supplementary) that were reused; and d) direct costs. Data is presented with its absolute and relative frequencies and confi dence intervals of 95 % normalised at 1000 patients/day. Results: 84 treatments were returned by 66 patients for a total of 139 preparations corresponding to 3,429 patients/day. This fi gure represents 24.5 (CI 95 %, 19.6 to 30.2) treatments that were prepared and not administered per 1,000 patients/day, mainly due to clinical causes (n = 47). Colon neoplasia and treatment with 5-fl uorouracil and levofolinic acid presented the highest number of returns. The returned preparations made up 1.45 % (CI 95 %, 1.2 to 1.7) of those produced. The percentage of reuse is 98 %, which results in savings of € 10,432.55 (90 % of the cost of the treatments that are returned). Conclusions: The application of quality, effectiveness and safety criteria to anti-neoplastic treatments that are prepared and returned to the Pharmacy Department allows a more effi cient preparation process.